Breaking News

CoronaVac Vaccine Booster Dose Induces Strong Immune Response

August 10, 2021 • 2:40 pm CDT
(Precision Vaccinations News)

Beijing-based SINOVAC Biotech Ltd. announced today the publication of two papers with findings from clinical studies on the immunogenicity, safety, and immune response of CoronaVac® in two- and three-dose vaccination schedules.

The results of these studies indicate that a third booster dose of CoronaVac induces a strong immune response in healthy adults with no serious adverse reactions related to the vaccine.

The first paper, titled Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years: interim results from a double-blind, randomized, placebo-controlled phase 2 clinical trial, includes published data on the immunogenicity and safety profile of a two-dose schedule, as well as interim results on immune persistence and the immunogenicity and safety of a third dose of CoronaVac in healthy adults aged 18 to 59 years old.

The second paper, titled A booster dose is immunogenic and will be needed for older adults who have completed two-doses vaccination with CoronaVac: a randomized, double-blind, placebo-controlled, phase 1/2 clinical trial, includes published data on the immunogenicity and safety profile of the third dose of CoronaVac in healthy adults aged 60 and above, as well as research on the immune persistence of two priming doses.

This research provides important scientific data and supplements existing research to help policymakers develop strategies for vaccine rollout and the timing of booster doses.

Sinovac Biotech Ltd. is a Beijing-based bio-high-tech company currently listed on the Nasdaq Global Select Market (NasdaqGS: SVA). Through its wholly-owned subsidiary, Kexing Holdings (Hong Kong) Co., Ltd., the company owns Beijing Kexing Biological Products Co., Ltd., Kexing (Dalian) Vaccine Technology Co., Ltd., Beijing Kexing Zhongwei Biotechnology Co., Ltd., and Kexing Holdings (Singapore) Co., Ltd. The company and Beijing Kexing Zhongyi Bio-Pharmaceutical Co., Ltd. have five enterprises and have four industrial bases in Haidian, Changping, Daxing, Beijing, and Dalian, Liaoning.




Medical Review by

Our Trust Standards: Medical Advisory Committee